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I
NCREASED UNDERSTANDING AND AWARENESS OF
congenital cardiac disease has allowed early identi-
fication of these children. Advances in surgi-
cal techniques, anesthesia, and medical treatment have
rendered the majority of forms of congenital cardiac
defects treatable. Therefore, the incidence of pulmon-
ary hypertension related to the Eisenmenger syndrome
should decrease. However, some patients need treat-
ment for pulmonary hypertension despite repair of
defects. Heart-lung1 and lung transplantation2 remain
the therapeutic options when medical therapy fails.
According to the registry of the International
Society for Heart and Lung Transplantation, 25% of
heart-lung and less than 1% of lung transplants have
been performed for adult patients with congenital
cardiac disease.3 Similarly, more than 40% of heart-
lung and 5% of lung transplants have been performed
in children with congenital cardiac anomalies.4 The
objective of this session is to address four major points:
the cost-benefit and risk-benefit issues for lung or
heart-lung transplantation versus currently available
medical treatments, the allocation policies for these
patients, the risk-benefit issue for lung versus heart-
lung transplant, and the use of ventricular assist
devices in patients with biventricular failure as to
allow successful isolated heart transplantation follow-
ing improvement of pulmonary hemodynamics.
Lung or heart-lung transplantation versus
medical treatment
In comparison with idiopathic pulmonary arterial
hypertension, the natural history of patients with
pulmonary hypertension associated with congenital
cardiac disease is considerably better, with a greater
than 60% survival rate being reported 20 years
following diagnosis. It has been also suggested that
adults with the Eisenmenger syndrome have a
more favorable hemodynamic profile and prognosis
than adults with the idiopathic form,5 with an 80%
and 40% survival respectively five and 25 years
following diagnosis. Furthermore, the Columbia
University group recently reported that long-term
infusion of epoprostenol improves hemodynamics
and the quality of life in patients with pulmon-
ary hypertension associated with congenital cardiac
defects.6 In contrast, the survival after lung or heart-
lung transplantation is approximately 50%
at five years,3 but it continues to decrease thereafter,
as opposed to heart transplant where survival at
one year is fairly predictive of rates observed at
five and ten years. The Papworth group evaluated
the potential survival benefits by reviewing 653
patients accepted for lung transplantation.7 Among
them, 76 subjects had the Eisenmenger syndrome.
They reported that lung transplantation confers a
significant survival benefit for patients with various
lung diseases except for the Eisenmenger syndrome.
However, these data primarily reflect outcomes in
adolescents and adults. Although post-transplant
outcomes are comparable, survival without trans-
plant in pediatric patients is likely to be worse, as in
a large single center series, 25% of patients were on
mechanical ventilation at transplant.8
While survival is the most important measure
for the success of transplantation, improving the
recipient’s quality of life is another important
objective of the procedure. Several studies have
shown improved quality of life after lung and heart-
lung transplantation.9,10 Gains diminish, however,
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with the onset of complications such as bronchiolitis
obliterans syndrome.11,12 No studies have investi-
gated the impact of transplantation on the quality of
life specifically for patients with congenital cardiac
disease and pulmonary hypertension.
The issue of cost-effectiveness must be analyzed
taking the quality of life into account, in particular
in view of the lifetime cost of care for the lung
transplant recipient estimated at about $425,000 in
the United States13 and $180,000 in the United
Kingdom.14 Investigators have attempted to deter-
mine the cost per year adjusted for the quality of
life.15,16 The emerging picture is that although the
lifetime follow-up of lung transplant recipients is
associated with high costs, it remains cost-effective
in view of the gain in terms of quality of life as
compared with standard care without transplanta-
tion. The lowest gain, however, has been observed
for secondary pulmonary hypertension.15 Thus,
although no clear survival benefit has been demon-
strated for patients with congenital cardiac disease,
recipients with advanced symptoms appear to
benefit in terms of the quality of life, but at
considerable cost. There may be a survival benefit in
pediatric patients who require mechanical ventila-
tion. Development of more effective therapies for
bronchiolitis obliterans may also lead to a survival
benefit.
Indication and allocation for lung and
heart-lung transplantation
The timing of referral is particularly difficult in
patients with congenital cardiac anomalies because
they are not a homogeneous group. Regarding the
Eisenmenger syndrome, some centers would follow
guidelines for idiopathic pulmonary arterial hyper-
tension proposed by the International Society for
Heart and Lung Transplantation,17 but it should be
emphasized that there is no general agreement on
this, as others would refer only patients with
advanced class IV symptoms.
Referral
> New York Heart Association functional class III
or IV, irrespective of the ongoing therapy
> Rapidly progressive disease.
Transplantation
> Persistent class III or IV symptoms on maximal
medical therapy
> Low (less than 350 meters) or declining six-
minute walk distance
> Cardiac index of less than 2 liters/min/m2
> Right arterial pressure exceeding 15mmHg.
Similar recommendations for children with the
Eisenmenger syndrome were included in a con-
sensus statement from major pediatric lung trans-
plant centers.18 The same document recommends
immediate referral for children with specific anom-
alies (i.e. pulmonary venous stenosis) because of
poor response to medical therapy.
Heart-lung transplantation is indicated for
severely symptomatic patients who are unlikely to
have a successful repair of congenital cardiac defects,
and patients with severely depressed left ventricular
function (left ventricular ejection fraction less than
35%).8,19 German groups, however, have performed
heart-lung transplantation as the procedure of
choice for these patients, resulting in similar
outcomes.20,21 Again, it should be emphasized that
other groups would not support this approach. In
the United States, the United Network for Organ
Sharing allocates lungs to adolescents and adults
based on a multi-factorial analysis of the waiting list
and transplant mortality.22 Children aged less than
12 years old continue to be allocated lungs based on
time accrued on the waiting list. There has been
increased allocation to recipients with idiopathic
pulmonary fibrosis and cystic fibrosis, and decreased
allocation to recipients with emphysema and pul-
monary hypertension.23 In the United States, heart-
lung candidates receive first priority for lungs when
allocated the heart and priority behind Status 1A
heart candidates when allocated the lungs. The heart
priority is unlikely to increase, as the waiting list
mortality for heart-lung transplant candidates is
comparable to lung candidates and much lower than
Status 1A or 1B heart candidates.24
Lung versus heart-lung transplantation
There are three transplant options for end-stage
patients; single lung transplantation with repair of
Patients with congenital heart disease and advanced pulmonary
vasculopathy presenting with severe class IV symptoms should be
counseled that quality of life benefit is likely. With the exception of
those patients requiring mechanical ventilation or until more
effective therapies for bronchiolitis obliterans are available, the
impact of transplantation on survival and the cost-benefit
relationship remain unclear.
Class: IIa. Level of evidence: C.
Patients with advanced pulmonary hypertension associated with
congenital heart disease should be referred and listed for lung or
heart-lung transplantation if they persist with class IV symptoms
(New York Heart Association) despite maximal medical therapy. In
particular, heart-lung transplantation should be considered for
patients who are unlikely to have a successful repair of the
congenital cardiac defects.
Class: IIa. Level of evidence: C.
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the cardiac defect, bilateral lung transplantation
with repair of the defect, and heart-lung transplan-
tation. Theoretical advantages with single lung
transplantation include shorter bypass time, thor-
acotomy instead of sternotomy, less bleeding, and
organ sparing.25 It is well recognized, however, that
single lung transplantation for pulmonary hyperten-
sion involves a potentially difficult post-operative
course and high mortality.19 Cardiac repair with
bilateral lung transplantation8,26 appears to be
associated with a better post-operative course, but
carries potential morbidity associated with longer
cardiopulmonary bypass. Heart-lung transplanta-
tion20,21 is a simpler operation as compared to
bilateral lung transplantation, but requires alloca-
tion of two organs from the scarce donor organ
supply, adds risk of cardiac graft coronary vasculo-
pathy and is less tolerant of ischemic time.
Several reports have shown similar survival between
bilateral lung transplantation and heart-lung trans-
plantation for pulmonary hypertensive patients.8,19,27
No single center has, however, transplanted a large
enough number of patients with Eisenmenger
syndrome. The Toronto group analyzed the Interna-
tional Society for Heart and Lung Transplantation and
United Network for Organ Sharing Joint Thoracic
Registry database which included 69, 106 and 430
single-lung, bilateral-lung and heart-lung transplanta-
tions respectively.28 This analysis suggests that heart-
lung transplantation appears to offer a survival benefit
for pulmonary hypertensive patients with ventricu-
lar septal defects and should be considered as the
operation of choice. Regarding pediatric patients with
congenital cardiac disease and advanced pulmonary
vasculopathy, the number of transplants reported by
the International Society for Heart and Lung Trans-
plantation4 is quite limited (less than 100) and the
major experience has been reported by the St. Louis
group. They reported that despite the complexity of
combined cardiac repair with bilateral lung transplan-
tation in 35 cases, and the resulting perioperative
morbidity, patients had similar outcomes as compared
with 16 patients who underwent heart-lung trans-
plantation.8
Ventricular assist devices and patients with
pulmonary hypertension and congenital
cardiac disease
Some patients with congenital cardiac disease have
altered pulmonary hemodynamics with increased
vascular resistance partly or totally related to left
ventricular dysfunction. Outcomes for isolated cardiac
transplantation are often poor in this scenario, so that
levels of pulmonary vascular resistance above 6 Wood
units m2 or a transpulmonary gradient exceeding
15mmHg are routinely considered as exclusion
criteria for this procedure. In these instances, heart-
lung transplantation appears as a therapeutic option.29
Recent reports of normalization of elevated pulmon-
ary vascular resistance in adults treated on a long-
term basis with ventricular assist devices30 raise the
possibility that similar improvement can occur in
children. Recently, the use of Berlin pediatric device in
two patients initially referred for heart-lung transplant
allowed isolated heart transplant with successful
outcome.31 Further studies are obviously required
before this approach can be recommended.
Alternatively, recipients with preoperatively in-
creased pulmonary vascular resistance might benefit
from short-term or long-term treatments with drugs
such as continuous intravenous epoprostenol, enteral
sildenafil, etc. started peri-operatively and maintained
for months. This approach has been successfully
attempted more than several times, and appears to be
promising in terms of avoiding heart-lung transplan-
tation. This would increase the likelihood of getting a
donor, as heart transplant would be carried out alone
instead of waiting for a heart-lung block. The
potential impact of this approach on outcomes
warrants further investigation.
Conclusion
Because of statistical impossibility to demonstrate a
clear survival benefit, lung and heart-lung trans-
plantation remain a procedure of last resort for
patients with advanced pulmonary vasculopathy
associated with congenital cardiac disease. Ongoing
development of therapies to improve pulmonary
hemodynamics in these patients will likely reduce
the numbers of patients requiring transplant in the
future. At present, lung and heart-lung transplant
should be considered in order to improve the
quality of life in selected patients.
Bilateral lung transplantation with repair of the cardiac defects is
favored over heart-lung transplantation for patients with congenital
heart disease and advanced pulmonary vasculopathy.
Class: IIb. Level of evidence: C.
Patients with congenital heart disease associated with left-sided
failure and elevated pulmonary vascular resistance not responsive
to an acute pulmonary vasodilator challenge should be considered
for heart-lung transplantation if pulmonary hemodynamics
cannot be improved by medical therapy or if medical therapy
cannot be administered for any reasons. The role of ventricular
assist devices to improve pulmonary hemodynamics requires
further investigation.
Class: IIb. Level of evidence: C.
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